Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 4
1991 1
1992 1
1994 2
1995 5
1996 1
1997 1
1998 1
2000 2
2001 3
2003 2
2004 2
2005 2
2006 2
2013 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
Fenaux P, Chomienne C, Degos L. Fenaux P, et al. Among authors: chomienne c, degos l. Semin Hematol. 2001 Jan;38(1):13-25. doi: 10.1016/s0037-1963(01)90002-2. Semin Hematol. 2001. PMID: 11172536 Review.
All-trans retinoic acid (ATRA) can induce complete remission (CR) in most patients with acute promyelocytic leukemia (APL) through in vivo differentiation of APL-blasts. ...It is also strongly suggested that maintenance treatmen …
All-trans retinoic acid (ATRA) can induce complete remission (CR) in most patients with acute promyelo …
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
Fenaux P, Chastang C, Chomienne C, Castaigne S, Sanz M, Link H, Löwenberg B, Fey M, Archim-Baud E, Degos L, et al. Fenaux P, et al. Among authors: chomienne c, degos l. Leuk Lymphoma. 1995 Feb;16(5-6):431-7. doi: 10.3109/10428199509054430. Leuk Lymphoma. 1995. PMID: 7787753 Review.
All transretinoic acid (ATRA) gives complete remission (CR) rates of 80 to 90% in newly diagnosed acute promyelocytic leukemia (APL). However, it has two major drawbacks (1) a rapid rise in WBC in some patients, with potentially fatal ATRA syndrome (2) …
All transretinoic acid (ATRA) gives complete remission (CR) rates of 80 to 90% in newly diagnosed acute promyelocytic …
Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.
de Botton S, Coiteux V, Chevret S, Rayon C, Vilmer E, Sanz M, de La Serna J, Philippe N, Baruchel A, Leverger G, Robert A, San Miguel J, Conde E, Sotto JJ, Bordessoule D, Fegueux N, Fey M, Parry A, Chomienne C, Degos L, Fenaux P. de Botton S, et al. Among authors: chomienne c, fenaux p, degos l. J Clin Oncol. 2004 Apr 15;22(8):1404-12. doi: 10.1200/JCO.2004.09.008. J Clin Oncol. 2004. PMID: 15084614 Clinical Trial.
PURPOSE: To determine the results of treatment combining all-trans-retinoic acid (ATRA) and chemotherapy (CT) in childhood acute promyelocytic leukemia (APL). ...CONCLUSION: ATRA combined with CT for induction and als …
PURPOSE: To determine the results of treatment combining all-trans-retinoic acid (ATRA) and chemothera …
Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
de Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X, Mediavilla JD, Recher C, Ades L, Quesnel B, Brault P, Fey M, Wandt H, Machover D, Guerci A, Maloisel F, Stoppa AM, Rayon C, Ribera JM, Chomienne C, Degos L, Fenaux P; European APL Group; PETHEMA Group. de Botton S, et al. Among authors: chomienne c, fenaux p, degos l. Leukemia. 2006 Jan;20(1):35-41. doi: 10.1038/sj.leu.2404006. Leukemia. 2006. PMID: 16307026 Clinical Trial.
We analyzed the incidence, presenting features, risk factors of extramedullary (EM) relapse occurring in acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) and chemotherapy by using a competing-ri …
We analyzed the incidence, presenting features, risk factors of extramedullary (EM) relapse occurring in acute promyelocytic …
Induction treatment of acute promyelocytic leukemia using all-trans retinoic acid. Controversies about dosage, advantages and side-effect management.
Dombret H, Castaigne S, Fenaux P, Chomienne C, Degos L. Dombret H, et al. Among authors: fenaux p, chomienne c, degos l. Leukemia. 1994;8 Suppl 3:S73-5. Leukemia. 1994. PMID: 7808030 Clinical Trial.
All-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) represents the leading example of targetted drugs for inducing an in vivo differentiation of malignancy (1,2). A fixed dose of 45 mg/m2/day was proposed for the …
All-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) represents the leading …
Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience.
Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, Sanz M, Guerci A, Miguel JS, Dela Serna J, Garo C, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P; European APL Group. Ades L, et al. Among authors: chomienne c, fenaux p, degos l. Leukemia. 2005 Feb;19(2):230-3. doi: 10.1038/sj.leu.2403597. Leukemia. 2005. PMID: 15565164 Clinical Trial.
We analyzed the outcome of patients aged more than 60 included in a multicenter trial in newly diagnosed acute promyelocytic leukemia (APL93 trial), which tested the role of early addition of chemotherapy to all trans retinoic a …
We analyzed the outcome of patients aged more than 60 included in a multicenter trial in newly diagnosed acute promyelocytic …
All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship.
Agadir A, Cornic M, Lefebvre P, Gourmel B, Jérôme M, Degos L, Fenaux P, Chomienne C. Agadir A, et al. Among authors: fenaux p, chomienne c, degos l. J Clin Oncol. 1995 Oct;13(10):2517-23. doi: 10.1200/JCO.1995.13.10.2517. J Clin Oncol. 1995. PMID: 7595702
PURPOSE: This study investigated the in vitro pharmacologic behavior and disposition kinetics of all-trans retinoic acid (ATRA) in acute myeloid leukemic (AML) cells, their sensitivity to its differentiating effect, and the in vivo response of …
PURPOSE: This study investigated the in vitro pharmacologic behavior and disposition kinetics of all-trans retinoic …
In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome.
Cassinat B, Chevret S, Zassadowski F, Balitrand N, Guillemot I, Menot ML, Degos L, Fenaux P, Chomienne C; European APL Group. Cassinat B, et al. Among authors: fenaux p, chomienne c, degos l. Blood. 2001 Nov 1;98(9):2862-4. doi: 10.1182/blood.v98.9.2862. Blood. 2001. PMID: 11675363 Free article.
Acute promyelocytic leukemia (APL) blasts possess a unique sensitivity to the differentiating effects of all-trans retinoic acid (ATRA). Multicenter trials confirm that the combination of differentiation and cytotoxic therapy …
Acute promyelocytic leukemia (APL) blasts possess a unique sensitivity to the differentiating effects of all- …
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M, Guerci A, San Miguel J, de la Serna J, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P. de Botton S, et al. Among authors: chomienne c, fenaux p, degos l. J Clin Oncol. 2005 Jan 1;23(1):120-6. doi: 10.1200/JCO.2005.03.127. Epub 2004 Nov 8. J Clin Oncol. 2005. PMID: 15534358
PURPOSE: To retrospectively determine the outcome of acute promyelocytic leukemia (APL) patients who underwent autologous or allogeneic stem-cell transplantation (SCT) during second complete remission. PATIENTS AND METHODS: Of 122 relapsing patients included …
PURPOSE: To retrospectively determine the outcome of acute promyelocytic leukemia (APL) patients who underwent autologo …
29 results